Your browser doesn't support javascript.
loading
Clinical consensus on treatments for transplant-ineligible newly diagnosed multiple myeloma: double-blinded Delphi panel.
Fonseca, Rafael; Rossi, Adriana; Medhekar, Rohan; Voelker, Jennifer; Homan, Trevor; Wilcock, Jessica; Karakusevic, Anna; Cochrane, James; Bridge, Daisy; Perry, Richard; Kaila, Shuchita; Davies, Faith E.
Afiliação
  • Fonseca R; Division of Hematology and Medical Oncology, Mayo Clinic in Arizona, Phoenix, AZ, USA.
  • Rossi A; Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Medhekar R; Janssen Scientific Affairs, Horsham, PA, USA.
  • Voelker J; Janssen Scientific Affairs, Horsham, PA, USA.
  • Homan T; Janssen Medical Affairs, Horsham, PA, USA.
  • Wilcock J; Adelphi Values PROVE, Bollington, UK.
  • Karakusevic A; Adelphi Values PROVE, Bollington, UK.
  • Cochrane J; Adelphi Values PROVE, Bollington, UK.
  • Bridge D; Adelphi Values PROVE, Bollington, UK.
  • Perry R; Adelphi Values PROVE, Bollington, UK.
  • Kaila S; Janssen Scientific Affairs, Horsham, PA, USA.
  • Davies FE; Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA.
Future Oncol ; : 1-12, 2024 May 20.
Article em En | MEDLINE | ID: mdl-38861282
ABSTRACT

Aim:

Obtain clinical consensus on factors impacting first-line prescribing for transplant-ineligible (TIE) patients with newly diagnosed multiple myeloma (NDMM). Materials &

methods:

A double-blinded, modified Delphi panel was employed. USA-based hematologists/oncologists who treat TIE patients with NDMM were selected as expert panelists.

Results:

Consensus was reached that patient frailty, performance status, comorbidities, treatment efficacy, and adverse event profile affect first-line prescribing. All panelists agreed it is important to use the most efficacious treatment first; 88% of panelists considered daratumumab-containing regimens the most efficacious. Panelists agreed treatment should be continued until progression while benefits outweigh risk.

Conclusion:

Findings reinforce the importance of using the most efficacious regimen upfront for TIE NDMM, and nearly all panelists considered daratumumab-containing regimens the most efficacious treatment.
The purpose of this study was to determine the latest clinician preferences and opinions on factors affecting initial treatment selection for people recently diagnosed with multiple myeloma and unable to receive a bone marrow transplant, and to understand challenges with current treatments used in clinical practice. A panel of doctors with an average of two decades of experience treating blood disorders and cancers were recruited as expert panelists. Experts discussed treatment options by completing two rounds of surveys on treatment and one round of discussion. All experts agreed that the most effective treatment should be used first. Most experts considered treatment containing the drug daratumumab to be the most effective. Experts agreed that treatment should be continued until the cancer worsens if the treatment offers more benefits than side effects.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article